Floatz logo

Tenofovir Alafenamide

HCC Patients After Curative Treatment With Low HBV Viral Load

Taipei Veterans General Hospital, TaiwanSmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

520 Active assets in the HCC Patients After Curative Treatment With Low HBV Viral Load cohort.

Asset / SponsorPhaseRating
Huaier Granule
Tongji Hospital
Phase 4BBB
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Carboplatin
AstraZeneca
Phase 4BB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

Tenofovir Alafenamide is also rated in:

HIV infectious diseaseDormant
BB
Indicative ·
71 / 100
View asset →
chronic hepatitis B virus infectionDormant
BB
Indicative ·
69 / 100
View asset →
hepatitis B virus infectionDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →